Healio

‘Major breakthrough’: Topical male pattern hair loss drug shows ‘meaningful’ hair regrowth

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...
Nasdaq

Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures

Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and ...
Nasdaq

Cosmo to Unveil First-of-its-Kind Clinical Study on the Use of GI Genius(TM) with Apple Vision Pro at Rush University Medical Center

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software ...
FiercePharma

Cosmo shares zoom with results from 2 male-pattern hair loss trials

Cosmo Pharmaceuticals has revealed topline results from two phase 3 trials which indicate that its topical cream clascoterone could become a game-changing treatment for male-pattern hair loss. The ...
Oil

Cosmo Energy taps Chiyoda for Chiba refinery CCS project study

Cosmo Energy Holdings Co. Ltd.’s Cosmo Oil Co. Ltd. has let a contract to Chiyoda Corp. to evaluate the potential for implementing infrastructure designed to separate and capture carbon dioxide (CO 2) ...